|
|
Robert L. Jilka, Robert S. Weinstein, Teresita Bellido, Paula Roberson, A. Michael Parfitt, Stavros C. Manolagas
J Clin Invest. 1999;
104(4):439
doi:10.1172/JCI6610
Abstract |
Full text
| PDF

T
he mass of regenerating tissues, such as bone, is critically dependent on the number of executive cells, which in turn is determined by the rate of replication of progenitors and the life-span of mature cells, reflecting the timing of death by apoptosis. Bone mass can be increased by intermittent parathyroid hormone (PTH) administration, but the mechanism of this phenomenon has remained unknown. We report that daily PTH injections in mice with either normal bone mass or osteopenia due to defective osteoblastogenesis increased bone formation without affecting the generation of new osteoblasts. Instead, PTH increased the life-span of mature osteoblasts by preventing their apoptosis — the fate of the majority of these cells under normal conditions. The antiapoptotic effect of PTH was sufficient to account for the increase in bone mass, and was confirmed in vitro using rodent and human osteoblasts and osteocytes. This evidence provides proof of the basic principle that the work performed by a cell population can be increased by suppression of apoptosis. Moreover, it suggests novel pharmacotherapeutic strategies for osteoporosis and, perhaps, other pathologic conditions in which tissue mass diminution has compromised functional integrity.J. Clin. Invest. 104:439-446 (1999).
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
About CrossRef
| Title and authors |
Publication |
Year |
. |
Local and systemic control of the osteoblast
Gordon J. Strewler |
J Clinic Invest |
2001 |
.
|
Osteoblast Apoptosis and Bone Turnover
J. M. Hock, V. Krishnan, J. E. Onyia, J. P. Bidwell, J. Milas, D. Stanislaus |
J Bone Miner Res |
2001 |
.
|
The Molecular Genetics of Bone Formation
Pierre J. Marie |
American Journal of PharmacoGenomics |
2001 |
.
|
How to prevent fractures in the individual with osteoporosis
M.K. Javaid, C. Cooper |
Best Pract Res Clin Rheumatol |
2001 |
.
|
Anabolic Agents to Treat Osteoporosis in Older People: Is There Still Place for Fluoride?. Fluoride for Treating Postmenopausal Osteoporosis. Haguenauer D, Welch V, Shea B, Tugwell P, (Cochrane Review) In: The Cochrane Library, issue 4, 2000. Oxford.
Gustavo Duque |
Journal of the American Geriatrics Society |
2001 |
.
|
Apoptosis may determine the release of skeletal alkaline phosphatase activity from human osteoblast-line cells
J. R. Farley, B. Stilt-Coffing |
Calcif Tissue Internat |
2001 |
.
|
Caspase-Dependent Cleavage of Cadherins and Catenins During Osteoblast Apoptosis
Irene Hunter, Duncan Mcgregor, Simon P. Robins |
J Bone Miner Res |
2001 |
.
|
The Loss of Smad3 Results in a Lower Rate of Bone Formation and Osteopenia Through Dysregulation of Osteoblast Differentiation and Apoptosis
Anita J. Borton, Joshua P. Frederick, Michael B. Datto, Xiao-Fan Wang, Robert S. Weinstein |
J Bone Miner Res |
2001 |
.
|
Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture
R.M.R Pereira, A.M Delany, E Canalis |
J Orthop Sports Phys Ther |
2001 |
.
|
Activated parathyroid hormone/parathyroid hormone–related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone
L.M. Calvi, N.A. Sims, J.L. Hunzelman, M.C. Knight, A. Giovannetti, J.M. Saxton, H.M. Kronenberg, R. Baron, E. Schipani |
J Clinic Invest |
2001 |
.
|
Socrates Papapoulos |
Curr Opin Clin Nutr Metab Care |
2001 |
.
|
Parathyroid Hormone Added to Established Hormone Therapy: Effects on Vertebral Fracture and Maintenance of Bone Mass After Parathyroid Hormone Withdrawal
F. Cosman, J. Nieves, L. Woelfert, C. Formica, S. Gordon, V. Shen, R. Lindsay |
J Bone Miner Res |
2001 |
.
|
Reconstituting Telomerase Activity Using the Telomerase Catalytic Subunit Prevents the Telomere Shorting and Replicative Senescence in Human Osteoblasts
Kazuo Yudoh, Hiroaki Matsuno, Fujio Nakazawa, Rie Katayama, Tomoatsu Kimura |
J Bone Miner Res |
2001 |
.
|
Decreased cellular activity and replicative capacity of osteoblastic cells isolated from the periarticular bone of rheumatoid arthritis patients compared with osteoarthritis patients
Kazuo Yudoh, Hiroaki Matsuno, Ryusuke Osada, Fujio Nakazawa, Rie Katayama, Tomoatsu Kimura |
Arth Rheumat |
2000 |
.
|
Novel treatments for osteoporosis
Ernesto Canalis |
J Clinic Invest |
2000 |
.
|
Therapeutic patenting for glucocorticoid-induced osteoporosis
Mark S Cooper, Paul M Stewart |
eotp |
2000 |
.
|
Corticosteroids and Fractures: A Close Encounter of the Third Cell Kind
Stavros C. Manolagas |
J Bone Miner Res |
2000 |
.
|
The parathyroid hormone, its fragments and analogues - potent bone-builders for treating osteoporosis
James Whitfield, Paul Morley, Gordon Willick |
Expert Opin Invest Drugs |
2000 |
.
|
Osteocyte and osteoblast apoptosis and excessive bone deposition accompany failure of collagenase cleavage of collagen
Weiguang Zhao, Michael H. Byrne, Yingmin Wang, Stephen M. Krane |
J Clinic Invest |
2000 |
.
|
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Lilian I. Plotkin, Robert S. Weinstein, A. Michael Parfitt, Paula K. Roberson, Stavros C. Manolagas, Teresita Bellido |
J Clinic Invest |
1999 |
.
|
|
|
|